Francesco De Rubertis is a Partner and co-founder of the firm's life sciences practice.
He joined Index in 1998 and has overseen all of the life sciences investment of the firm. Present and past Index portfolio companies include: Genmab A/S (Coph: GEN.CO), CellZome Inc. (sold to GlaxoSmithKline), Molecular Partners A/G, Aegerion Inc. (Nasdaq: AEGR), Addex Pharmaceuticals SA (Swx: ADXN), PanGenetics B/V (sold to Abbott Pharmaceuticals), Micromet Inc. (sold to Amgen), Bioxell SpA (sold to Cosmo Pharmaceuticals) and Parallele Inc. (sold to Affymetrix). Francesco has served on most of these boards.
Prior to joining Index, Francesco was involved in post-doctoral research in genetics at the Whitehead Institute, Massachusetts Institute of Technology (MIT). He is also the author of several publications in international scientific journals.
Francesco has a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva. He is a CFA charter holder, and is a member of the Strategic Advisory Board of the University of Geneva.
Francesco was named by BioWorld as one of 28 "movers and shakers" predicted to shape the biotechnology industry over the next two decades.